PHARMACIE DE BARJAC : revenue, balance sheet and financial ratios

PHARMACIE DE BARJAC is a French company founded 40 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in BARJAC (30430), this company of category PME shows in 2021 a revenue of 3.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DE BARJAC (SIREN 333019156)
Indicator 2025 2024 2023 2021 2020 2019 2018 2017
Revenue N/C N/C N/C 2 968 261 € 2 867 494 € 2 908 505 € N/C 2 681 579 €
Net income 187 541 € 78 319 € 150 110 € 187 414 € 216 634 € 217 556 € 143 780 € 195 245 €
EBITDA N/C N/C N/C 254 640 € 258 827 € 250 229 € N/C 286 437 €
Net margin N/C N/C N/C 6.3% 7.6% 7.5% N/C 7.3%

Revenue and income statement

In 2025, PHARMACIE DE BARJAC generates positive net income of 188 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 195 k€ -> 188 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

187 541 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 106%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 28%. The balance between equity and debt is satisfactory.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

105.698%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

28.282%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

50.8%

Solvency indicators evolution
PHARMACIE DE BARJAC

Sector positioning

Debt ratio
105.7 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average +35 pts over 3 years

In 2025, the debt ratio of PHARMACIE DE BARJAC (105.70) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
28.28% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average -22 pts over 3 years

In 2025, the financial autonomy of PHARMACIE DE BARJAC (28.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 125.63. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

125.628

Liquidity indicators evolution
PHARMACIE DE BARJAC

Sector positioning

Liquidity ratio
125.63 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Watch -5 pts over 3 years

In 2025, the liquidity ratio of PHARMACIE DE BARJAC (125.63) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DE BARJAC

Positioning of PHARMACIE DE BARJAC in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE DE BARJAC is estimated at 2 979 111 € (range 2 021 638€ - 4 674 635€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
2021k€ 2979k€ 4674k€
2 979 111 € Range: 2 021 638€ - 4 674 635€
NAF 5 année 2025

Valuation method used

Net Income Multiple
187 541 € × 15.9x = 2 979 111 €
Range: 2 021 639€ - 4 674 636€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DE BARJAC with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DE BARJAC

What is the revenue of PHARMACIE DE BARJAC ?

The revenue of PHARMACIE DE BARJAC in 2021 is 3.0 M€.

Is PHARMACIE DE BARJAC profitable?

Yes, PHARMACIE DE BARJAC generated a net profit of 188 k€ in 2025.

Where is the headquarters of PHARMACIE DE BARJAC ?

The headquarters of PHARMACIE DE BARJAC is located in BARJAC (30430), in the department Gard.

Where to find the tax return of PHARMACIE DE BARJAC ?

The tax return of PHARMACIE DE BARJAC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DE BARJAC operate?

PHARMACIE DE BARJAC operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.